Form 4: Coya Therapeutics Director Granted Stock Options

Coya Therapeutics Director Dov A. Goldstein MD was granted 10,000 stock options with an exercise price of $5.65, vesting in one year.

Summary

• Dov A. Goldstein MD, a Director of Coya Therapeutics, Inc. (COYA), was granted 10,000 stock options.
• The stock options have an exercise price of $5.65 per share.
• The grant date for these options was January 2, 2026.
• The options will vest 100% on the first anniversary of the grant date, subject to continuous service.
• The options become exercisable on January 2, 2027, and expire on January 2, 2036.
• The underlying security for these options is Common Stock, par value $0.0001 per share.
• Following this transaction, Dov A. Goldstein MD directly beneficially owns 10,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating continued commitment and alignment of interests between the board and shareholders. It is a routine compensation event and not indicative of major operational or financial shifts.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the value of the options increases with the company's stock price.

Future Outlook

The vesting schedule of the stock options, contingent on continuous service, indicates an expectation for the director's ongoing involvement with the company for at least one year from the grant date.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to attract and retain talent and align their interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including biotechnology, to incentivize long-term performance and align interests with shareholders.
• The vesting schedule, with 100% vesting on the first anniversary, is a common structure for such grants, similar to practices seen at comparable early-stage biotech companies.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The stock options will vest on January 2, 2027, at which point the director will be able to exercise them.

Key Dates

Keywords

Coya Therapeutics, COYA, stock options, director compensation, insider transaction, Form 4